Skip to main content

Research Repository

Advanced Search

Separating chemotherapy-related developmental neurotoxicity from cytotoxicity in monolayer and neurosphere cultures of human fetal brain cells (2016)
Journal Article
Ivanov, D. P., Al-Rubai, A., Grabowska, A. M., & Pratten, M. K. (2016). Separating chemotherapy-related developmental neurotoxicity from cytotoxicity in monolayer and neurosphere cultures of human fetal brain cells. Toxicology in Vitro, 37, 88-96. https://doi.org/10.1016/j.tiv.2016.09.007

Chemotherapy-induced neurotoxicity can reduce the quality of life of patients by affecting their intelligence, senses and mobility. Ten percent of safety-related late-stage clinical failures are due to neurological side effects. Animal models are poo... Read More about Separating chemotherapy-related developmental neurotoxicity from cytotoxicity in monolayer and neurosphere cultures of human fetal brain cells.

Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance (2016)
Journal Article
Secrier, M., Li, X., de Silva, N., Eldridge, M. D., Contino, G., Bornschein, J., …Grimmond, S. M. (2016). Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nature Genetics, 48(10), https://doi.org/10.1038/ng.3659

Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have thus far been disappointing owing to a lack of robust stratification methods. Whole-genome sequencing (WGS) analysis of 129 cases demonstrated that this is a heterog... Read More about Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.

3-dimensional patient-derived lung cancer assays reveal resistance to standards-of-care promoted by stromal cells but sensitivity to histone deacetylase inhibitors (2016)
Journal Article
Onion, D., Argent, R. H., Reece-Smith, A. M., Craze, M. L., Pineda, R. G., Clarke, P. A., …Grabowska, A. M. (2016). 3-dimensional patient-derived lung cancer assays reveal resistance to standards-of-care promoted by stromal cells but sensitivity to histone deacetylase inhibitors. Molecular Cancer Therapeutics, 15(4), doi:10.1158/1535-7163.MCT-15-0598

There is a growing recognition that current preclinical models do not reflect the tumor microenvironment in cellular, biological, and biophysical content and this may have a profound effect on drug efficacy testing, especially in the era of molecular... Read More about 3-dimensional patient-derived lung cancer assays reveal resistance to standards-of-care promoted by stromal cells but sensitivity to histone deacetylase inhibitors.


;